| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
Peimine targets multiple pathways including inflammatory signaling pathways. As a steroidal alkaloid, it likely interacts with various cellular targets including ion channels, receptors, and enzymes involved in inflammation and cell survival. Peimine has been shown to exhibit anti-inflammatory effects by modulating cytokine production and inflammatory mediator expression. It may also have effects on airway smooth muscle, contributing to its expectorant and antitussive properties. The compound's specific molecular targets have not been fully characterized.
|
|---|---|
| ln Vitro |
In vitro, Peimine exhibits anti-inflammatory activity by modulating cytokine production and inflammatory mediator expression. It has been shown to inhibit the production of pro-inflammatory cytokines and reduce the expression of inflammatory mediators. Peimine also exhibits anti-tumor activity, potentially through the modulation of cell proliferation and apoptosis pathways. However, specific IC50 values or detailed activity data is not provided in the available sources.
|
| ln Vivo |
In vivo, Peimine has been used in traditional Chinese medicine for its expectorant and antitussive properties. It exhibits anti-inflammatory and analgesic activities in animal models. Peimine may also have anti-tumor activity, though specific in vivo efficacy data is limited. The compound's traditional use suggests a favorable safety profile at appropriate doses, but comprehensive preclinical studies would be required for therapeutic development.
|
| Enzyme Assay |
For Peimine, standard cell-free assays include enzyme inhibition assays for targets such as cyclooxygenase (COX), lipoxygenase (LOX), or other inflammatory enzymes. The compound's ability to inhibit these enzymes can be measured using appropriate substrates and detection methods. Receptor binding assays may also be used to identify specific molecular targets.
|
| Cell Assay |
For Peimine, standard cellular assays involve treatment of immune cells (e.g., macrophages) or cancer cell lines with the test compound for 24-48 hours. Cytokine production (e.g., TNF-α, IL-6, IL-1β) is measured by ELISA. Inflammatory mediator expression (e.g., COX-2, iNOS) is assessed by western blot or qPCR. Cell viability and proliferation are assessed using MTT or CellTiter-Glo assays.
|
| Animal Protocol |
For in vivo evaluation of Peimine, standard animal models include models of inflammation (e.g., carrageenan-induced paw edema), cough models, and tumor xenograft models. The compound is typically administered orally or intraperitoneally. Inflammatory markers, cough frequency, tumor growth, and survival are assessed.
|
| ADME/Pharmacokinetics |
Detailed pharmacokinetic data for Peimine is not provided in the available sources. As a steroidal alkaloid with moderate lipophilicity, it would be expected to have reasonable oral absorption. Comprehensive pharmacokinetic studies would be required for therapeutic development.
|
| Toxicity/Toxicokinetics |
Detailed toxicology data for Peimine is not provided in the available sources. As a naturally occurring alkaloid, it may have a favorable safety profile at moderate doses based on traditional use. However, comprehensive toxicological evaluation would be required for therapeutic development. The compound is for research use only and not for therapeutic applications.
|
| References |
|
| Additional Infomation |
Verticine is an alkaloid. It has been reported that fritillary alkaloids are found in fritillaria, Fritillaria monoflora, and other organisms with relevant data.
Peimine is a natural steroidal alkaloid isolated from Fritillaria species. It has been studied for its anti-inflammatory, analgesic, and anti-tumor activities. Peimine is used in traditional Chinese medicine for its expectorant and antitussive properties. No regulatory approval has been identified. |
| Molecular Formula |
C27H45NO3
|
|---|---|
| Molecular Weight |
431.661
|
| Exact Mass |
431.339
|
| CAS # |
23496-41-5
|
| PubChem CID |
131900
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
568.4±50.0 °C at 760 mmHg
|
| Melting Point |
233-234ºC
|
| Flash Point |
275.3±28.8 °C
|
| Vapour Pressure |
0.0±3.5 mmHg at 25°C
|
| Index of Refraction |
1.591
|
| LogP |
4.45
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
31
|
| Complexity |
715
|
| Defined Atom Stereocenter Count |
13
|
| SMILES |
C[C@H]1CC[C@H]2[C@@]([C@H]3CC[C@@H]4[C@H]([C@@H]3CN2C1)C[C@H]5[C@H]4C[C@@H]([C@@H]6[C@@]5(CC[C@@H](C6)O)C)O)(C)O
|
| InChi Key |
IUKLSMSEHKDIIP-BZMYINFQSA-N
|
| InChi Code |
InChI=1S/C27H45NO3/c1-15-4-7-25-27(3,31)21-6-5-17-18(20(21)14-28(25)13-15)11-22-19(17)12-24(30)23-10-16(29)8-9-26(22,23)2/h15-25,29-31H,4-14H2,1-3H3/t15-,16-,17+,18+,19-,20-,21-,22-,23+,24-,25-,26+,27-/m0/s1
|
| Chemical Name |
(1R,2S,6S,9S,10S,11S,14S,15S,17S,18S,20S,23R,24S)-6,10,23-trimethyl-4-azahexacyclo[12.11.0.02,11.04,9.015,24.018,23]pentacosane-10,17,20-triol
|
| Synonyms |
Dihydroisoimperialine; Verticine; 5α-Cevane-3β,6α,20-triol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~115.83 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.79 mM) (saturation unknown) in 10% DMSO + 40% PEG300 +5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 + to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3166 mL | 11.5832 mL | 23.1664 mL | |
| 5 mM | 0.4633 mL | 2.3166 mL | 4.6333 mL | |
| 10 mM | 0.2317 mL | 1.1583 mL | 2.3166 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
